Stock Traders Buy Large Volume of Call Options on Tempus AI (NASDAQ:TEM)

Tempus AI, Inc. (NASDAQ:TEM) saw some unusual options trading activity on Wednesday. Investors purchased 51,813 call options on the stock. This is an increase of 264% compared to the typical volume of 14,225 call options.

Insider Activity

In related news, EVP Andrew Polovin sold 51,504 shares of Tempus AI stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total value of $2,183,254.56. Following the completion of the transaction, the executive vice president now directly owns 246,085 shares in the company, valued at approximately $10,431,543.15. This trade represents a 17.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David R. Epstein sold 620 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total value of $25,922.20. Following the sale, the director now directly owns 27,894 shares in the company, valued at approximately $1,166,248.14. This represents a 2.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,037,702 shares of company stock valued at $89,449,651 in the last ninety days.

Hedge Funds Weigh In On Tempus AI

Hedge funds have recently made changes to their positions in the business. First Horizon Advisors Inc. bought a new position in shares of Tempus AI during the 3rd quarter worth approximately $30,000. FNY Investment Advisers LLC acquired a new stake in shares of Tempus AI during the fourth quarter worth $67,000. IFP Advisors Inc bought a new position in Tempus AI during the 4th quarter worth approximately $76,000. Vestor Capital LLC bought a new stake in shares of Tempus AI in the 3rd quarter valued at $153,000. Finally, Stifel Financial Corp bought a new position in Tempus AI in the third quarter valued at approximately $218,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Trading Up 0.5 %

Tempus AI stock opened at $61.85 on Wednesday. Tempus AI has a 12 month low of $22.89 and a 12 month high of $79.49. The business has a 50 day moving average price of $44.20 and a two-hundred day moving average price of $48.58. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Piper Sandler restated a “neutral” rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Wolfe Research assumed coverage on shares of Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Guggenheim assumed coverage on Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 price target for the company. Finally, Needham & Company LLC restated a “buy” rating and set a $56.00 target price on shares of Tempus AI in a report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $56.36.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.